Imprinted Gene Markers for Bladder Cancer Invasiveness Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods lack the ability to accurately distinguish between invasive and non-invasive bladder cancer, which is crucial for determining the appropriate treatment approach and prognosis.
Innovation Solution
The use of imprinted genes Grb10 and Diras3 as markers, where the ratio of their expressed quantities with copy number variations, known as the bladder infiltration factor, is calculated to determine the invasiveness of bladder cancer, allowing for differentiation between non-invasive, mixed, and invasive types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used, then diagnosis can be performed, but the ability to accurately distinguish invasive from non-invasive bladder cancer is insufficient
Solution Approach 1:
The invention changes the detection parameter from general tumor markers to specific imprinted gene expression levels (Grb10 and Diras3). By measuring the expression quantities of these specific genes and calculating their ratio, the method achieves precise differentiation between invasive and non-invasive bladder cancer, directly resolving the contradiction between detection accuracy and diagnostic reliability
Solution Approach 2:
The invention introduces imprinted gene expression ratios as an intermediary parameter between traditional diagnostic methods and treatment decisions. The ratio of Grb10 to Diras3 expression serves as a molecular mediator that translates complex tumor biology into a quantifiable metric, enabling accurate distinction between invasive and non-invasive cases while improving both measurement precision and diagnostic reliability
2Measurement precision
If molecular marker analysis is performed to improve diagnosis accuracy, then detection precision improves, but the complexity of the detection method increases
Solution Approach 1:
The invention extracts and focuses on only two specific imprinted genes (Grb10 and Diras3) from the complex landscape of potential tumor markers. By selecting and measuring only these two genes rather than analyzing numerous markers simultaneously, the method achieves high molecular-level detection accuracy while keeping the detection system relatively simple and clinically feasible
Data Source
AI summary
Provided in the present application are a marker used to detect invasive bladder cancer and an application thereof, the marker being imprinted gene Grb10 and/or imprinted gene Diras3. The marker of the present application can accurately detect the invasiveness of a bladder cancer, thereby providing guidance on the choice of the surgical method to be used on the bladder cancer, reducing the chance of post-operative recurrence and metastasis. The detection method of the present application is different from its immunohistochemical counterparts in that it can reduce false positives and other negative effects. Moreover, targeting drugs or methods that are found to work at the loss-of-imprinting-affected sites of bladder-cancer-invasiveness-related imprinted genes to silence, delete, or rearrange those genes can be used to guide subsequent treatment and medication.